ホーム>>Signaling Pathways>> GPCR/G protein>> Prostaglandin Receptor>>L 888607

L 888607

カタログ番号GC31768

L 888607 は、強力で、選択的で、安定しており、経口的に活性な CRTH2 アゴニストです。

Products are for research use only. Not for human use. We do not sell to patients.

L 888607 化学構造

Cas No.: 860033-06-3

サイズ 価格 在庫数 個数
5mg
$297.00
在庫あり
10mg
$482.00
在庫あり
25mg
$1,020.00
在庫あり
50mg
$1,576.00
在庫あり
100mg
$2,225.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

L 888607 is a potent, and selective CRTH2 (also known as DP2) agonist with a Ki of 0.8±0.4 nM.

L 888607 (L-888,607) is administered to mice either intravenously (i.v.) or orally (p.o.) to determine its pharmacokinetic profile over an 8-h period. After an intravenous administration of 5 mg/kg L 888607, blood analysis reveals a peak level (Cmax) of 36.1 μM, a half-life (t1/2) of 2.9 h, a trough level at 8 h (C8h) of 3.5 μM, and an area under the curve0-8h of 87.1 μM. After oral administration of 20 mg/kg L 888607, blood analysis reveals a Cmax of 31.6 μM, a t1/2 of 4 h, a C8h at 8 h of 15.4 μM, an area under the curve0-8h of 166 μM, and a bioavailability of 48%[1].

[1]. Gervais FG, Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol. 2005 Jun;67(6):1834-9. [2]. Ulven T, et al. Novel CRTH2 antagonists: a review of patents from 2006 to 2009. Expert Opin Ther Pat. 2010 Nov;20(11):1505-30.

レビュー

Review for L 888607

Average Rating: 5 ★★★★★ (Based on Reviews and 20 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for L 888607

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.